

*Biopharmaceutical Contract Manufacturing 2009:  
Expanding Markets, New Capacities and  
Improved Performance*

Table of Contents

Presented by

**HighTech Business Decisions**

3150 Almaden Expressway, Suite 223, San Jose, CA 95118

Tel: (408) 978-1035 Fax: (408) 978-8925

[www.hightechdecisions.com](http://www.hightechdecisions.com)

**June 2009**

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## FORWARD AND ACKNOWLEDGMENTS

HighTech Business Decisions conducted the market research and wrote the report, *Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance* to provide a comprehensive market analysis of the biopharmaceutical contract manufacturing market worldwide. The research was specifically designed to understand strategies for biomanufacturing, outsourcing practices and future plans, services needed and capacity requirements, decision criterion, current suppliers and collaborations, timelines, expenditures, and future strategies. The complete analysis, based on both user and supplier primary research, includes market size and growth, major players, user strategies and requirements, trends and technologies, and users' future plans for meeting biopharmaceutical manufacturing requirements. In-depth data collected from both users and suppliers allowed for an objective and thorough analysis.

We thank the 77 respondents from pharmaceutical, biotechnology, and contract manufacturing companies who took the time to share their insights, opinions, and future plans with us. We thank our sponsoring companies, who supported this project with their ideas, suggested topics, and funding for the first few months of this five-month project.

The sponsoring companies are, in alphabetical order, as follows:

Aspex Division: Asahi Glass Co., Ltd.	Human Genome Sciences, Inc.
Boehringer Ingelheim GmbH	KBI Biopharma Inc.
Cook Pharmica	Laureate Pharma Inc.
Diosynth Biotechnology	ProBioGen AG
DSM Pharmaceuticals, Inc.	Sandoz GmbH

The following HighTech Business Decisions analysts and staff made important contributions to this research and report:

### Analysts

Forrest Blocker, Ph.D.	User interviews
Amy Boggs, Ph.D.	User interviews
D.J. Cassell, Ph.D.	User and contractor interviews and analysis
Shauna Farr-Jones, Ph.D.	User interviews
Jennifer Hartigan, Ph.D.	User and contractor interviews and analysis
Richard G. Khoury, Ph.D.	User and contractor interviews
Lynne Sopchak, Ph.D.	User and contractor interviews and analysis

### Staff

William Downey, MBA	Project management, analysis, and report
Cindy Liu, MBA	Analysis and report
Dawn Miles, MBA	Project management, analysis, and production

We hope that our clients obtain significant value from this report to help ensure the success of their future business.

Sincerely,

William Downey, MBA  
President

**June 2009**

This report is Copyright protected by HighTech Business Decisions. All rights reserved. Printed and bound in the United States of America. Neither this report, nor parts of it, may be reproduced without written permission from HighTech Business Decisions.

HighTech Business Decisions has exercised due care in compiling this report, which is based on publicly available information as well as information submitted by individual companies. The company interview write-ups and profiles contained in this report are not intended to be a complete description of each company, but a paraphrased synopsis of interviews conducted with these companies from January to April 2009, combined with submitted material. The publishers have taken due care to ensure the accuracy of this information, but shall not be held liable for any consequential damages arising from the material in this report.

Copies of this report may be ordered from HighTech Business Decisions. To place an order, please call HighTech Business Decisions at (408) 978-1035, or visit [www.HighTechDecisions.com](http://www.HighTechDecisions.com).

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## TABLE OF CONTENTS

---

<b>Chapter 1:</b>	<b>EXECUTIVE SUMMARY</b>	
	<b>1.1 Introduction</b>	<b>1-1</b>
	<b>1.2 Market Overview</b>	<b>1-2</b>
	1.2.1 Introduction	1-2
	1.2.2 Industry Drivers	1-2
	1.2.3 Market Size	1-4
	<b>1.3 Summary of Customer Needs</b>	<b>1-5</b>
	1.3.1 Products	1-5
	1.3.2 Outsourcing Strategies	1-7
	1.3.3 Outsourcing Budgets	1-8
	1.3.4 Impact of Current Financial Crisis	1-10
	1.3.5 Industry Trends and Observations	1-11
	<b>1.4 Summary of Contractors' Capabilities</b>	<b>1-12</b>
	1.4.1 Annual Revenue Ranges	1-12
	1.4.2 Technology Capabilities	1-13
	1.4.3 Capacity Increases	1-14
	1.4.4 Impact of World-Wide Financial Development	1-15
	1.4.5 Expectations for the Future of the Industry	1-17
<hr/>		
<b>Chapter 2:</b>	<b>METHODOLOGY, DEFINITIONS, AND ACRONYMS</b>	
	<b>2.1 Research Objectives</b>	<b>2-1</b>
	<b>2.2 Research Methodology</b>	<b>2-1</b>
	<b>2.3 Definition of Biopharmaceutical Manufacturing</b>	<b>2-3</b>
	<b>2.4 Acronyms</b>	<b>2-4</b>
<hr/>		
<b>Chapter 3:</b>	<b>BIOPHARMACEUTICAL CONTRACT MANUFACTURING: MARKET OVERVIEW</b>	
	<b>3.1 Introduction</b>	<b>3-1</b>
	<b>3.2 Suppliers: The Contract Biomanufacturers</b>	<b>3-2</b>
	3.2.1 Types of Contract Biomanufacturing Companies	3-2
	3.2.2 Major Players: Contract Biomanufacturing Companies	3-3
	3.2.3 Organizational Changes in the Industry	3-7
	3.2.4 Technologies and Services	3-8
	3.2.5 Contract Biomanufacturers' Capacities	3-9
	3.2.6 Revenues and Profit Margins	3-12

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## TABLE OF CONTENTS (continued)

---

<b>Chapter 3:</b>	<b>3.3 The Customers: Pharmaceutical and Biotechnology Companies</b>	<b>3-13</b>
	3.3.1 <i>Outsourced Biomanufacturing</i>	3-13
	3.3.2 <i>Outsourcing Biomanufacturing by Technology</i>	3-15
	3.3.3 <i>Examples of Contractors Used by Client Companies</i>	3-17
	3.3.4 <i>Customers' Future Outsourcing Expectations</i>	3-20
	3.3.5 <i>Capacity</i>	3-21
	<b>3.4 Industry Drivers</b>	<b>3-26</b>
	3.4.1 <i>Capacity</i>	3-26
	<b>3.5 Market Size</b>	<b>3-32</b>
	3.5.1 <i>Estimates of Market Size Based on Customer Spending</i>	3-32
	3.5.2 <i>Estimates of Market Size Based on Contractor Revenues</i>	3-33
	3.5.3 <i>Market Size by Technology and Service Categories</i>	3-33
	<b>3.6 Market Growth Forecasts</b>	<b>3-35</b>
	<b>3.7 Trends in the Biopharmaceutical Contract Mfg. Market</b>	<b>3-36</b>
	3.7.1 <i>Industry Opportunities and Challenges</i>	3-36
	3.7.2 <i>Overall Industry Trends</i>	3-37
<hr/>		
<b>Chapter 4:</b>	<b>PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: CLIENT ANALYSIS</b>	
	<b>4.1 Introduction</b>	<b>4-1</b>
	<b>4.2 Respondent Company Backgrounds</b>	<b>4-2</b>
	4.2.1 <i>Respondents' Titles and Experience</i>	4-2
	4.2.2 <i>Locations and Sites</i>	4-4
	4.2.3 <i>Respondents' Clinical and Commercial Products</i>	4-6
	4.2.4 <i>Respondents' Outsourced Products</i>	4-9
	<b>4.3 Biomanufacturing Needs</b>	<b>4-15</b>
	4.3.1 <i>Current and Forecast Biomanufacturing Needs</i>	4-15
	4.3.2 <i>Current Internal Capacity and Plans to Build</i>	4-21
	4.3.3 <i>Average and Planned Capacity Utilization Rates</i>	4-24
	4.3.4 <i>Preclinical Products</i>	4-25
	4.3.5 <i>Future Production Technology Requirements</i>	4-27
	<b>4.4 Biomanufacturing Strategies</b>	<b>4-29</b>
	4.4.1 <i>Overall Biomanufacturing Strategies</i>	4-29
	4.4.2 <i>Basis for Outsourcing Decisions</i>	4-33
	4.4.3 <i>Contract Decisions</i>	4-37
	4.4.4 <i>Potential for Second Source Contracting</i>	4-40
	4.4.5 <i>Anticipated Changes in Overall Strategies</i>	4-44

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## TABLE OF CONTENTS (continued)

---

<b>Chapter 4:</b>	<b>4.5 Outsourcing Biomanufacturing</b>	<b>4-47</b>
	4.5.1 <i>Percentage Outsourced and Expected to Be Outsourced</i>	4-47
	4.5.2 <i>Current and Anticipated Needs for Outsourced Services</i>	4-50
	4.5.3 <i>Process Development Services Outsourced</i>	4-53
	4.5.4 <i>Process Development Services Sought From a CMO</i>	4-56
	4.5.5 <i>Need for Cell Line Development Services</i>	4-59
	4.5.6 <i>Most Important Service Contractors Can Offer</i>	4-61
	4.5.7 <i>New Services Sought in a Contractor</i>	4-65
	<b>4.6 Biomanufacturing Technologies</b>	<b>4-69</b>
	4.6.1 <i>Yields: Current and Forecast Changes</i>	4-69
	4.6.2 <i>Contractor Proprietary Expression Systems</i>	4-76
	4.6.3 <i>Trends in Proprietary Media Systems</i>	4-79
	4.6.4 <i>Trends in Novel Designer Cell Substrates</i>	4-84
	4.6.5 <i>Disposable Bioreactor Scale and Barriers</i>	4-85
	4.6.6 <i>Release Procedure for APIs Produced at the Contractor</i>	4-90
	4.6.7 <i>Evaluation of New Technologies</i>	4-94
	<b>4.7 Contractor Selection</b>	<b>4-100</b>
	4.7.1 <i>How Potential Contract Partners are Found</i>	4-100
	4.7.2 <i>Essential Characteristics of a Contract Mfg. Organization</i>	4-101
	4.7.3 <i>Choosing Between Two Contractors</i>	4-109
	4.7.4 <i>Searching For New Contractors</i>	4-112
	4.7.5 <i>Undesirable CMO Behaviors or Attitudes</i>	4-117
	4.7.6 <i>Location: Preference for Geographic Region</i>	4-125
	4.7.7 <i>Preference for Working with an Asian CMO</i>	4-132
	4.7.8 <i>Tax Benefit Effect on Location</i>	4-143
	4.7.9 <i>Ideal Bioreactor and Column Scale at a Contractor</i>	4-146
	4.7.10 <i>Preference for One-Stop-Shop</i>	4-153
	4.7.11 <i>Importance of API and Fill and Finish at one Location</i>	4-157
	<b>4.8 Contractor Pricing</b>	<b>4-160</b>
	4.8.1 <i>Typical Timelines and Pricing</i>	4-160
	4.8.2 <i>Outsourced Services</i>	4-166
	4.8.3 <i>Number of Validation Batches Willing to Pay For</i>	4-166
	4.8.4 <i>Process Validation/Characterization Payments</i>	4-171
	4.8.5 <i>Royalty Payments for Proprietary Microbial High Expression Systems</i>	4-174
	4.8.6 <i>Preferred Time Range for Duration of CMO Contract</i>	4-176
	4.8.7 <i>Cost Models</i>	4-180
	<b>4.9 Contractor Relationships</b>	<b>4-182</b>
	4.9.1 <i>Current Contractors Used by Service</i>	4-182
	4.9.2 <i>Favorite Contractors</i>	4-186
	4.9.3 <i>Plans to Increase/Decrease Number of CMOs Used</i>	4-193
	4.9.4 <i>Top Concerns Regarding CMOs Meeting Expectations</i>	4-194
	4.9.5 <i>Biggest Opportunity for Improvement</i>	4-200

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## TABLE OF CONTENTS (continued)

---

<b>Chapter 4:</b>	<b>4.10 Outsource Spending</b>	<b>4-206</b>
	4.10.1 <i>Outsourcing Budgets</i>	4-206
	4.10.2 <i>Outsourcing Budgets by Technology</i>	4-208
	4.10.3 <i>Outsourcing Budgets by Service</i>	4-210
	<b>4.11 Future Trends and Expectations</b>	<b>4-213</b>
	4.11.1 <i>Impact of Current Financial Crisis on Make or Buy Decisions</i>	4-213
	4.11.2 <i>Challenges Facing Biomanufacturing</i>	4-219
	4.11.3 <i>Product or Innovation Impact on Next Year's Operations</i>	4-227
	4.11.4 <i>The Future of the Contract Biomanufacturing Industry</i>	4-230

---

<b>Chapter 5:</b>	<b>BIOPHARMACEUTICAL CONTRACT MANUFACTURERS</b>	
	<b>5.1 Introduction</b>	<b>5-1</b>
	5.1.1 <i>Study Participants</i>	5-1
	5.1.2 <i>Types of Suppliers</i>	5-2
	5.1.3 <i>Locations</i>	5-4
	5.1.4 <i>Acquisitions and Organizational Changes</i>	5-10
	5.1.5 <i>Revenues</i>	5-11
	<b>5.2 Technologies and Capacities Offered</b>	<b>5-13</b>
	5.2.1 <i>Technologies Offered</i>	5-13
	5.2.2 <i>Types of Products Produced</i>	5-16
	5.2.3 <i>Contract Manufacturers' Current Capacities</i>	5-18
	5.2.4 <i>Contract Manufacturers' Expansion Plans</i>	5-23
	5.2.5 <i>Investment Decision Factors</i>	5-25
	<b>5.3 Contract Manufacturers' Service Capabilities</b>	<b>5-27</b>
	5.3.1 <i>Percentage of Business From Each Service Category</i>	5-27
	5.3.2 <i>Changes in Service Offerings</i>	5-29
	5.3.3 <i>Fill-and-Finish Capabilities</i>	5-31
	5.3.4 <i>Special Expertise in Process Development</i>	5-33
	5.3.5 <i>Manufacturing Capability of Commercial Products</i>	5-37
	5.3.6 <i>In-House Analytical Development and Testing Capability</i>	5-39
	5.3.7 <i>Experience with Monoclonal Antibody versus Recombinant Proteins</i>	5-42
	5.3.8 <i>Top Trends Leading Changes in Operations</i>	5-43

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## TABLE OF CONTENTS (continued)

---

<b>Chapter 5:</b>	<b>5.4 Manufacturing Technologies</b>	<b>5-48</b>
	5.4.1 <i>Proprietary Expression Systems and Other IP</i>	5-48
	5.4.2 <i>Importance of In-House R&amp;D to Generate IP</i>	5-51
	5.4.3 <i>Failed cGMP Batches</i>	5-54
	5.4.4 <i>Meeting Regulatory Compliance Requirements</i>	5-56
	5.4.5 <i>Opinion on Role of Disposables in Large Scale Mfg.</i>	5-58
	5.4.6 <i>Opinion on New Designer Cell Lines</i>	5-62
	5.4.7 <i>Probability of High-Titer Commercial Cell Culture Process</i>	5-65
	5.4.8 <i>Efforts to Increase Scalability/Flexibility</i>	5-67
	5.4.9 <i>Expected Process Timelines</i>	5-71
	<b>5.5 Customers</b>	<b>5-74</b>
	5.5.1 <i>Clients Served</i>	5-74
	5.5.2 <i>Characteristics of the Customer Base</i>	5-75
	5.5.3 <i>Percentage of Business by World Regions</i>	5-78
	5.5.4 <i>Changes in the Customer Relationship</i>	5-80
	<b>5.6 Marketing</b>	<b>5-83</b>
	5.6.1 <i>New Business Win Rates</i>	5-83
	5.6.2 <i>Strengths and Weaknesses</i>	5-85
	5.6.3 <i>Trade Shows</i>	5-89
	5.6.4 <i>Future Growth and Expansion</i>	5-90
	<b>5.7 Pricing</b>	<b>5-92</b>
	5.7.1 <i>Price Structures</i>	5-92
	5.7.2 <i>Payment Arrangements Other Than Fee-For-Service</i>	5-95
	5.7.3 <i>Request for Quotes</i>	5-96
	5.7.4 <i>Product Changeover</i>	5-99
	5.7.5 <i>Gross Profit Margin Targets</i>	5-102
	5.7.6 <i>Expected Return on Sales</i>	5-103
	<b>5.8 Future Industry Trends</b>	<b>5-104</b>
	5.8.1 <i>Emergence of Biomanufacturing In Developing Countries</i>	5-104
	5.8.2 <i>Individual Roles in Global Outsourcing</i>	5-111
	5.8.3 <i>Impact of Biosimilars</i>	5-113
	5.8.4 <i>Impact of World-Wide Financial Development</i>	5-117
	5.8.5 <i>Expectations for the Biomanufacturing Regulatory Environment</i>	5-122
	5.8.6 <i>Expectations of Industry Growth</i>	5-126
	5.8.7 <i>Sustainability of the CMO Model</i>	5-129
	5.8.8 <i>Expectations for the Contract Biomanufacturing Industry</i>	5-133

# **Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance**

## **TABLE OF CONTENTS (continued)**

---

**Appendix A:** Write-Ups of Interviews with 48 Pharmaceutical and Biotechnology Company  
BioManufacturing Directors Worldwide, Unnamed and Edited for Confidentiality

**Appendix B:** Directory of Biopharmaceutical Contract Manufacturers

**Appendix C:** Interview Guide for Pharmaceutical and Biotechnology Company  
Respondents

**Appendix D:** Interview Guide for Biopharmaceutical Contract Manufacturers

---

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF TABLES

---

### Chapter 1

1.3-1	Users' Opinions on Future of the Industry	1-11
1.4-1	Future Trends Noted by CMO Respondents	1-17

### Chapter 2

2.2-1	Market Research Steps	2-2
2.4-1	List of Acronyms	2-4

### Chapter 3

3.2-1	Respondents' Top Biopharmaceutical Contractors Manufacturers	3-4
3.2-2	Examples of Changes or Events in the CMO Industry in 2007 & 2008	3-7
3.2-3	Major Contract Biomanufacturing Technology Categories	3-9
3.2-4	Biopharmaceutical Contract Manufacturing Industry Capacity Estimates	3-10
3.2-5	Examples of New Capacity for Contract Manufacturing	3-11
3.3-1	Examples of Customer Companies and Their Contract Biomanufacturers	3-17
3.3-2	Examples of Pharmaceutical/Biotechnology Companies Building Capacity	3-22
3.3-3	Estimates of Totaled Needs for Outsourced Volumes by Respondents	3-24
3.3-4	Estimates of Needs for Outsourced Volumes for the Worldwide Industry	3-26
3.4-1	Outsourced Mfg. Capacity vs Needs: Mammalian Cell Culture	3-27
3.4-2	Outsourced Mfg. Capacity vs Needs: Microbial Fermentation	3-30
3.5-1	Worldwide 2009 Market Size for Contract BioManufacturing: Spending	3-32
3.5-2	Worldwide 2009 Market Size for Contract BioManufacturing: Revenues	3-33
3.5-3	Market Size by Technology Category	3-34
3.5-4	Market Size by Service Category	3-34
3.7-1	Observations on Industry Trends	3-38

### Chapter 4

4.1-1	Respondent Pharmaceutical and Biotechnology Companies	4-2
4.2-1	Respondents' Titles	4-3
4.2-2	Respondent Locations	4-4
4.2-3	Number of Biomanufacturing Sites at Respondent Companies	4-5
4.2-4	Number of Products Produced Using Microbial Technologies	4-6
4.2-5	Number of Products Produced Using Mammalian Technologies	4-6
4.2-6	Types of Respondents' Products by Production Technology	4-9
4.2-7	Outsourced Products by Phase by Year	4-11
4.2-8	Number of Products Outsourced by Tank Size in 2009: Respondent Companies with No Biomanufacturing Sites	4-12
4.2-9	Number of Products Outsourced by Tank Size in 2009: Respondent Companies with One Biomanufacturing Site	4-12
4.2-10	Number of Products Outsourced by Tank Size in 2009: Respondent Companies with Multiple Biomanufacturing Sites	4-13
4.2.11	Types of Products Outsourced by Respondents in 2009	4-14

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF TABLES (continued)

---

### Chapter 4

4.3-1	Respondents' Current and Expected Capacity Needs for Outsourced Products: Large Tank Sizes, Mammalian Cell Culture	4-16
4.3-2	Respondents' Current and Expected Capacity Needs for Outsourced Products: Smaller Tank Sizes, Mammalian Cell Culture	4-17
4.3-3	Respondents' Current and Expected Capacity Needs for Outsourced Products: Large Tank Sizes, Microbial Fermentation	4-19
4.3-4	Respondents' Current and Expected Capacity Needs for Outsourced Products: Smaller Tank Sizes, Microbial Fermentation	4-20
4.3-5	Current Mammalian (Batch) Capacity and Expansions	4-22
4.3-6	Current Microbial Capacity and Expansions	4-23
4.3-7	Current Mammalian (Perfusion) Capacity and Expansions	4-23
4.3-8	Summary: Current Capacity and Expansions at Respondent Sites	4-24
4.3-9	Average Capacity Utilization Rates	4-24
4.3-10	Number of Respondents' Preclinical Products by Production Technology	4-26
4.3-11	Expected Changes in Technologies Used	4-28
4.4-1	Criteria for Choosing Between Internal versus Outsourced Manufacturing	4-30
4.4-2	Criteria for Basing Outsourcing Decisions	4-34
4.4-3	Outsource Preferences	4-37
4.4-4	Rational for Adding a Second Contract Supplier	4-40
4.5-1	Averaged Percentages of Outsourced Production by Year by Technology	4-48
4.5-2	Services Currently Outsourced	4-51
4.5-3	Services Planned Outsourced	4-52
4.5-4	No Plans to Outsource Services	4-52
4.5-5	Summary of Service Categories Based on Number of Products	4-53
4.5-6	Reasons for Outsourcing Process Development	4-55
4.5-7	Process Development Services Sought From a CMO	4-57
4.5-8	Factors Contributing to the Outsourcing of Cell Line Development	4-60
4.5-9	Most Important CMO Service	4-62
4.5-10	New CMO Services	4-66
4.6-1	Expression Levels Reported by Respondents in Grams per Liter	4-70
4.6-2	Expression Levels Reported for Mammalian MAb and rProtein Products	4-70
4.6-3	Impact of Increases in Yields	4-72
4.6-4	Methods to Improve Yields	4-74
4.6-5	Preference for CMO to have Proprietary Expression Platforms	4-77
4.6-6	Preference for Use of Proprietary Media Systems	4-81
4.6-7	Barriers to the Adoption of Disposable Bioreactors	4-87
4.6-8	Resources Dedicated to Evaluation of New Technologies	4-94
4.6-9	Length of Time to Implement New Technologies into Bioprocessing	4-98
4.7-1	Search Modes for CMOs	4-100
4.7-2	Meetings Attended and Journals Read when Searching for a CMO	4-100
4.7-3	Essential Characteristics for Choosing a CMO	4-102
4.7-4	Weighted Characteristics by Number of Manufacturing Sites	4-104
4.7-5	Choosing Between Two Contractors	4-110
4.7-6	Frequency and Motivation for a Seeking a New CMO	4-113

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF TABLES (continued)

---

### Chapter 4

4.7-7	Undesirable CMO Behaviors or Attributes	4-118
4.7-8	Factors for Choosing a CMO in a Different Geographic Region	4-127
4.7-9	Factors Deciding the Location of Large-Scale Manufacturing	4-130
4.7-10	Circumstances under Which Respondents Would Work with an Asian CMO	4-135
4.7-11	Influences on Ideal Bioreactor and Column Size for Non-Commercial and Commercial Biomanufacturing	4-147
4.8-1	Tank Sizes for Products Outsourced in 2009	4-162
4.8-2	Prices Paid for Products Outsourced in 2009	4-164
4.8-3	Typical Timelines and Spending per Project: Mammalian Cell Culture	4-165
4.8-4	Typical Timelines and Spending per Project: Microbial Fermentation	4-165
4.8-5	Process Validation/Characterization Payments in Preparation for Regulatory Filing	4-171
4.8-6	Cost Models Used for Outsourced Services	4-180
4.9-1	Contract Manufacturers Used By Respondents	4-182
4.9-2	Contract Manufacturers Preferred by Respondents	4-187
4.9-3	Top Issues Clients Have with CMOs	4-195
4.9-4	Opportunities for CMO Improvement	4-200
4.10-1	Expenditures on Outsourcing of Biopharmaceutical Production: 2009	4-208
4.10-2	Expenditures on Outsourcing of Biopharmaceutical Production: 2011	4-208
4.10-3	Average Percentage of Budgets Spent on Each Technology	4-209
4.10-4	Weighted Average Percentage of Budgets Spent on Each Technology	4-210
4.10-5	Simple Average: Percentages of Budgets by Service Expected in 2009	4-211
4.10-6	Simple Average: Percentages of Budgets by Service Expected in 2011	4-211
4.10-7	Weighted Average: Percentages of Budgets by Service Expected in 2009	4-212
4.10-8	Weighted Average: Percentages of Budgets by Service Expected in 2011	4-212
4.11-1	Challenges Facing Biomanufacturing	4-220
4.11-2	Technology Impacts on Operations	4-227
4.11-3	Opinions on the Future of the Contract Biomanufacturing Industry	4-233

### Chapter 5

5.1-1	Respondents from Companies Offering Contract Biomanufacturing Services	5-1
5.1-2	Types of Biopharmaceutical Contract Manufacturers	5-3
5.1-3	Contract Biomanufacturers: Headquarter Locations	5-5
5.1-4	Summary of Respondents' 49 Sites Worldwide	5-6
5.1-5	Examples of Company Changes in Contract Biomanufacturing in 2007/2008	5-10
5.1-6	2008 Revenues for Contract Biomanufacturers in US\$M	5-12
5.2-1	Averaged Percentages of Business from Biopharmaceutical Technologies	5-14
5.2-2	Types of Products Manufactured by Respondent Contractors	5-17
5.2-3	Microbial Fermentation Capacity at 16 Respondents' Facilities in 2009	5-19
5.2-4	Mammalian Cell Culture Capacity at 28 Respondents' Facilities in 2009	5-21
5.2-5	Summary of Specialized Technologies Offered By Contractors	5-22
5.2-6	New Capacity Expected: 2009 to 2012	5-23
5.2-7	Investment Decision Factors	5-25

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF TABLES (continued)

---

### Chapter 5

5.3-1	Respondents Offering Each Service and Percentage of Business: 2009	5-28
5.3-2	Respondents Indicating Changes in Services Over the Last Two Years	5-30
5.3-3	Respondents Expecting Changes in Services Over the Next Two Years	5-30
5.3-4	Special Expertise in Process Development	5-33
5.3-5	Manufacture and Regulatory Approval of Commercial Products	5-37
5.3-6	Analytical Development Capacity and Types of Assays Outsourced	5-39
5.3-7	Tops Trends Influencing Changes in Contract Manufacturing Operations	5-44
5.4-1	Specifically Mentioned Benefits of Developing IP and Innovative Processes	5-51
5.4-2	Agencies that Have Audited CMOs as Mentioned by Respondents	5-56
5.4-3	Benefits of Using Disposable in Contract Manufacturing	5-59
5.4-4	Benefits and Issues of Using New Designer Cell Lines	5-62
5.4-5	Efforts Improving Operations by Changing Scale or Flexibility	5-68
5.4-6	Process Timelines	5-72
5.5-1	Number of Clients in 2008	5-75
5.5-2	Customers by Average Percentage of Business	5-76
5.5-3	Types of Customers Served and Number of Products: Large Contractors	5-76
5.5-4	Types of Customers Served and Number of Products: Small Contractors	5-77
5.5-5	Average Percentage of Business by Customer Location	5-78
5.5-6	Average Percentage of Business from the World Regions	5-79
5.5-7	Changes in Contractor-Customer Relationships	5-80
5.6-1	New Business Development Win Rate by Contactor Size	5-83
5.6-2	Top CMO Strengths	5-85
5.6-3	Top CMO Weaknesses	5-86
5.6-4	Top Trade Shows for Finding Quality Leads and Technical Information	5-89
5.6-5	CMO Growth and Expansion Plans	5-90
5.7-1	Pricing Methods	5-92
5.7-2	Payment Arrangements Contractors Offer Customers	5-95
5.7-3	Gross Profit Margin	5-102
5.8-1	Current Status and Factors Limiting Contract Biomanufacturing in Developing Countries	5-106
5.8-2	Global Role Anticipated by CMO Respondents	5-111
5.8-3	Impact of Biosimilars	5-114
5.8-4	Regulatory Changes Anticipated by CMO Respondents	5-124
5.8-5	Averaged Expectations of Growth: 2009 to 2012	5-127
5.8-6	Ways to Sustain the CMO Model	5-130
5.8-7	Industry Prospects and Trends Noted by CMO Respondents	5-134

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF FIGURES

---

### Chapter 1

1.2-A	Worldwide Biopharmaceutical Contract Manufacturing Capacity	1-3
1.2-B	Size of the Worldwide Biopharmaceutical Contract Manufacturing Market	1-5
1.3-A	Number of Respondents' Biopharmaceutical Products by Phase	1-6
1.3-B	Respondents' Preclinical Products by Production Technology	1-6
1.3-C	Key Outsourcing Decision Criteria by Percentage of Respondents	1-8
1.3-D	Average Percentage of Outsourced Production	1-9
1.3-E	Numbers of Respondents Increasing, Decreasing, or Keeping the Same Outsource Percentage	1-9
1.3-F	Impact of the Current Financial Crisis	1-10
1.3-G	Effects of Financial Crisis	1-11
1.4-A	29 Contract Biomanufacturers' Annual Revenue Ranges in 2008	1-13
1.4-B	Technology Comparisons: Average Weighted Percentage of Business 2009	1-12
1.4-C	Reaction to Worldwide Financial Developments	1-15
1.4-D	Impact of Financial Situation	1-16

### Chapter 3

3.2-A	Worldwide Biopharmaceutical Contract Manufacturing Capacity	3-11
3.3-A	Number of Products Outsourced vs Produced In-House in 2009	3-14
3.3-B	Outsourced Products by Development Stage in 2009	3-14
3.3-C	Percentage of Respondents' Portfolio Outsourced by Production Technology	3-15
3.3-D	Tank Sizes Required for Outsourced Microbial Fermentation Products	3-16
3.3-E	Tank Sizes Required for Outsourced Mammalian Cell Culture Products	3-16
3.3-F	Simple Averaged Expected Percentages of Overall Outsourced Production	3-21
3.3-G	Trends by Number of Products Outsourced by Phase	3-23
3.3-H	Trends by Number of Products Outsourced by Technology	3-24
3.4-A	Mammalian Outsourcing Demand vs Contract Capacity: 2009 to 2014	3-27
3.4-B	Mammalian Outsourcing Demand vs Contract Capacity: 2003 to 2014	3-28
3.4-C	Microbial Outsourcing Demand vs Contract Capacity: 2009 to 2014	3-30
3.4-D	Microbial Outsourcing Demand vs Contract Capacity: 2003 to 2014	3-31
3.6-A	Size of the Worldwide Biopharmaceutical Contract Manufacturing	3-36

### Chapter 4

4.2-A	Number of Biomanufacturing Sites per Respondent Company	4-5
4.2-B	Number of Respondents' Products by Technology and Phase	4-7
4.2-C	Respondents' Biopharmaceutical Products by Phase	4-8
4.2-D	Respondents' Biopharmaceutical Products by Technology, Company Type	4-8
4.2-E	Number of Products Outsourced vs Produced In-House	4-10
4.2-F	Outsourced Products by Phase in 2009	4-11
4.2-G	Tanks Sizes Required for Outsourced Mammalian Cell Culture Products	4-13
4.2-H	Tanks Sizes Required for Outsourced Microbial Fermentation Products	4-14
4.3-A	Summation of Outsourced Volumes Required	4-21
4.3-B	Respondents' Preclinical Products by Production Technology	4-25
4.3-C	Technology Usage Patterns	4-28

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF FIGURES (continued)

---

### Chapter 4

4.4-A	Key Outsourcing Decision Criteria by Percentage of Respondents	4-30
4.4-B	Key Criteria for Basing Outsourcing Decisions	4-34
4.4-C	Overview of Respondents' Outsourcing Decisions	4-38
4.4-D	Respondents' General Expectation of Their Future Outsourcing Changes	4-44
4.4-E	Specific Factors and Changes in Outsourcing Strategies	4-45
4.5-A	Average Percentages of Outsourced Production	4-47
4.5-B	Average Percentages of Mammalian vs. Microbial Outsourced Production	4-49
4.5-C	Numbers of Respondents Increasing, Decreasing, or Keeping the Same Outsourcing Percentage	4-50
4.5-D	Average Percentage of Process Development that is Outsourced	4-54
4.5-E	Respondents' Process Development Outsource Strategies	4-54
4.6-A	Changes in Expression Yields in the Last Two Years	4-71
4.6-B	Yield Improvement Programs in Place	4-74
4.6-C	Preference for CMO to have Proprietary Expression Platforms	4-76
4.6-D	Preference for Use of Proprietary Medial Systems	4-80
4.6-E	Preference for Use of Proprietary Medial Systems by Manufacturing Sites	4-80
4.6-F	Trends in Novel Designer Cell Substrates	4-84
4.6-G	Maximum Feasible Single Use Bioreactor Size	4-86
4.6-H	Release Testing done at CMO, In-House or Outsourced	4-91
4.6-I	Final Release of API, In-House or CMO	4-91
4.7-A	Ranking of Price as an Important Criterion	4-102
4.7-B	Top Five First-Ranked Criteria for Selecting a CMO	4-103
4.7-C	Top Five Weighted Characteristics by Number of Manufacturing Sites	4-105
4.7-D	Percent of Related Criteria, Quality, Proven Capability and Expertise	4-105
4.7-E	Frequency of Searching for a New CMO.	4-113
4.7-F	Length of Time Needed to Contract a New CMO	4-115
4.7-G	Switching or Non Use Caused by Negative Attributes of CMOs	4-119
4.7-H	Advantages of Working with a CMO in the Same Geographic Region	4-125
4.7-I	Advantage of Geographic Proximity by Number of Manufacturing Sites	4-126
4.7-J	Preferences for Working with an Asian CMO	4-133
4.7-K	Acceptance of an Asian CMO by Companies by Number of Manufacturing Sites	4-134
4.7-L	Working with a CMO who Subcontracts to Asia	4-139
4.7-M	Phase of Development for Accepting Asian CMO	4-141
4.7-N	Effect of Tax Benefit on Choosing Location for Manufacturing	4-144
4.7-O	Effect of Tax Benefits by Number of Manufacturing Sites	4-144
4.7-P	Ideal Bioreactor Size for Non-Commercial and Commercial Fermentation and Cell Culture	4-147
4.7-Q	Ideal Column Size for Non Commercial and Commercial Microbial Fermentation	4-148
4.7-R	Distribution of Ratios of Bioreactor over Column Size	4-149
4.7-S	Bioreactor versus Column Size for Fermentation	4-150
4.7-T	Bioreactor versus Column Size for Cell Culture	4-150

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF FIGURES (continued)

---

### Chapter 4

4.7-U	Preference for a One-Stop-Shop	4-154
4.7-V	Preference for One-Stop-Shop By Number of Manufacturing Sites	4-154
4.7-W	Co-Location of API Manufacture and Fill and Finish	4-157
4.7-X	Co-Location of API Manufacture and Fill and Finish by Number of Manufacturing Sites	4-158
4.8-A	Types of Cultures Outsourced	4-160
4.8-B	Breakdown of Clinical Phase for Mammalian Outsourced Manufacture	4-161
4.8-C	Breakdown of Clinical Phase for Microbial Outsourced Manufacture	4-161
4.8-D	Timeline Expected for Production of Outsourced Mammalian Cell Culture	4-163
4.8-E	Timeline Expected for Production of Outsourced Microbial Cell Culture	4-163
4.8-F	Outsourced Services	4-166
4.8-G	Number of Paid for Batches to get Three Consecutive for US Regulatory Filing	4-167
4.8-H	Number of Paid for Batches to get Five Consecutive for EU Regulatory Filing	4-168
4.8-I	Process Validation/Characterization Payments in Preparation for Regulatory Filing	4-172
4.8-J	Willing to Pay Royalties for Proprietary Microbial High Expression Systems	4-174
4.8-K	Average Duration of a CMO Contract – Commercial	4-177
4.8-L	Average Duration of a CMO Contract – Clinical	4-177
4.9-A	Change in Number of CMOs Used in the Next Three to Five Years	4-193
4.10-A	Expectations Regarding Changes in Outsourcing Budgets: 2009 to 2011	4-207
4.10-B	Average Percentage of Budgets Spent on Each Technology: 2009 to 2011	4-209
4.11-A	Impact of the Current Financial Crisis	4-214
4.11-B	Financial Crisis Impact by Number of Manufacturing Sites	4-215
4.11-C	Effect of Financial Crisis	4-216
4.11-D	The Future of Biopharmaceutical Contract Manufacturing	4-231
4.11-E	Factors that will Affect CMO Capacity	4-232

### Chapter 5

5.1-A	Year Respondent Company Entered into CMO Business	5-4
5.1-B	Contract Biomanufacturers' Annual Revenue Ranges in US\$ in 2008	5-12
5.1-C	Revenue Growth Rates as Reported by Respondents: 2007 to 2008	5-13
5.2-A	Technology Comparisons: Average Weighted Percentage of Business	5-15
5.2-B	Technology Comparisons: Average Percentage of Business: 2009 by Group	5-15
5.2-C	Technology Comparisons: Average Percentage of Business: 2011 by Group	5-16
5.2-D	Individual Microbial Fermentation Capacity Utilization Rates	5-20
5.2-E	Individual Mammalian Cell Culture Capacity Utilization Rates	5-21
5.2-F	Summary of Current and Future Capacity at Surveyed Contractor Facilities	5-24
5.3-A	Average Percentage of Revenue from Each Service Category	5-29
5.3-B	Fill-and-Finish Capabilities	5-31
5.3-C	Companies with Approved Commercial Products	5-38
5.3-D	Location of Approval of Commercial Products	5-38
5.3-E	Types of Analytical Assays Outsourced	5-39
5.3-F	Monoclonal Antibody versus Recombinant Protein Experience	5-43

# Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance

## LIST OF FIGURES (continued)

---

### Chapter 5

5.4-A	Proprietary Expression Systems	5-49
5.4-B	Value of Developing IP around Innovative Processes	5-51
5.4-C	Drivers for Developing Innovative Technologies	5-52
5.4-D	Failed GMP Batches	5-55
5.4-E	Use of Disposables in Manufacturing	5-58
5.4-F	Maximum Size of Disposable Bioreactors	5-59
5.4-G	Probability of 5 g/L Commercial Cell Culture Processes in Next Five Years	5-66
5.4-H	Expansion of Scalability or Flexibility	5-68
5.4-I	Cell Line Development/First Clone Timeline	5-72
5.4-J	Process Development Timeline	5-73
5.4-K	Technology Transfer Timeline	5-73
5.4-L	Order to Start of cGMP Manufacture Timeline	5-74
5.5-A	Number of Clients Served in 2008	5-75
5.5-B	Percentage of Business from Different Customer Groups	5-77
5.5-C	Percentage of Business from World Regions: Large and Small Contractors	5-79
5.6-A	New Business Development Win Rates	5-83
5.7-A	Risk and Reward Sharing Relationships	5-93
5.7-B	Request for Quote Response	5-97
5.7-C	Time to Change from Product A to Product B	5-100
5.7-D	How Product Change Time is Charged	5-100
5.7-E	Targeted and Achieved Profit Margins	5-103
5.7-F	Expected Return on Sales	5-104
5.8-A	Summary of Views on Competitiveness of Contractors in Developing Countries	5-105
5.8-B	Impact of Biosimilars on Contractors' Growth	5-114
5.8-C	Reaction to Worldwide Financial Developments	5-118
5.8-D	Impact of Financial Situation	5-119
5.8-E	Contract Biomanufacturers Expected Continued Regulatory Changes	5-123
5.8-F	Expectations of Company Growth: 2009 to 2012	5-127